drugset
drugset / Trial / NCT02814565

Cyclobenzaprine HCl Extended Release 15 mg Versus Placebo in Treatment of Cervical and/or Lower Back Pain Due to Muscle Spasms of Local Origin

NCT02814565 ↗

Phase 3 Completed 180 enrolled Takeda
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study was to assess the effect of cyclobenzaprine hydrochloride (HCl) extended release (CER) 15 mg capsule once daily in participants with muscle spasms associated with acute painful musculoskeletal conditions.

Timeline

Start
2016-10-12
Primary completion
2017-02-10
Completion
2017-03-14

Drugs

EvaluationDrugModalityDoseRoute
Subject cyclobenzaprine Small molecule 15 mg Oral

Indications

No indication recorded.